Verve Therapeutics Inc. (NASDAQ:VERV) currently has a daily average trading volume of 742.78K but it saw 836444 shares traded on Thursday. With a market cap of 1.07B USD, stock’s current market price of $16.92 came falling about -0.76 while comparing to the previous closing price of $17.05. In past 52 weeks, the stock remained buoying in the range of price level as high as $43.00 and as low as $10.70. In the recent trading on the day, stock has struck highest price mark of $17.21 while lowest mark touched by it was $16.70.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
Taking a look at 20-day trading activity of Verve Therapeutics Inc. (VERV) gives us an average price of $18.70, while its current price level is -60.65% below from 52-week high level whereas it is 58.13% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $20.58 while that of 200 days or SMA-200 reads an average of $25.36. A closer look into the stock’s movement over the week reveals that its volatility is standing at 7.68% during that period while stretching the period over a month that decreases to 7.03%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 36.70 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Cantor Fitzgerald which initiated the stock as “Neutral” in its note to investors issued on February 01, 2023, recommending a price target of $21 for it. Credit Suisse also issued its recommendations for the stock as it initiated the price target for the stock is $48.
Over the week, VERV’s stock price is moving -2.70% down while it is -22.24% when we observe its performance for the past one month. Year-to-date it is -12.56% down and over the past year, the stock is showing a downside performance of -19.43%.
The latest quarterly earnings report issued by the company was for quarter ended 9/29/2022, when its quarterly earnings per share (EPS) of -$0.79 beaten by the consensus estimate of -$0.74 for the same. For VERV, analysts are forecasting an EPS-growth rate of 32.60% for current year and estimate for EPS growth in next year is -1.70%.
Currently, Verve Therapeutics Inc.’s total number of outstanding shares is 61.55M with 9.94% of that held by the insiders while 106.17% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -30.10% and return on equity (ROE) at -36.50%. Stock has a price to book (P/B) ratio of 1.89 while price to sale or P/S ratio amounts to 560.68. Its return on asset (ROA) is -31.10% on average.
A filing at the U.S. Securities and Exchange Commission revealed that SPDR S&P Biotech ETF came shrinking its share ownership by -0.88% in the Verve Therapeutics Inc. (VERV) decreasing its stake to 5.09% with control over 27870.0 shares in the company. As per SEC documents, SPDR S&P Biotech ETF shunned 3,134,109 of company’s common stock of worth $59.55 million as per recent closing price of the stock. SPDR S&P Biotech ETF is not the only institutional holder which restructured its stake in Verve Therapeutics Inc., as ARK Genomic Revolution ETF dumped 2,716,984 shares of worth $51.62 million to bring its holdings to a total of 2082.0 shares. In the most recent quarter, ARK Innovation ETF came cutting its stake by -1.58% in the company and now holds 1.51 million or 2.45% of the company’s stake having worth of about 28.65 million.
